

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/213153 A1

(43) International Publication Date
13 October 2022 (13.10.2022)

(51) International Patent Classification:

C12N 15/113 (2010.01) C12Q 1/6811 (2018.01)
C12N 15/11 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/AU2022/050310

(22) International Filing Date:

08 April 2022 (08.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2021901027 08 April 2021 (08.04.2021) AU
2021903431 27 October 2021 (27.10.2021) AU

(71) Applicant: HUDSON INSTITUTE OF MEDICAL
RESEARCH [AU/AU]; 27-31 Wright Street, Clayton, Vic-
toria 3168 (AU).

(72) Inventor: GANTIER, Michael Paul Marie; c/- Hudson
Institute of Medical Research, 27-31 Wright Street, Clayton,
Victoria 3168 (AU).

(74) Agent: FPA PATENT ATTORNEYS PTY LTD; Level
46, 101 Collins Street, Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- of inventorship (Rule 4.17(iv))

(54) Title: OLIGONUCLEOTIDES

(57) Abstract: The present disclosure relates to methods of selecting, designing or modifying oligonucleotides so that they inhibit cyclic GMP-AMP synthase (cGAS), Toll-Like Receptor 3 (TLR3), Toll-Like Receptor 7 (TLR7), Toll-Like Receptor 8 (TLR8) and/or 5 Toll-Like Receptor 9 (TLR9), or potentiate Toll-Like Receptor 8 (TLR8). Additionally, the present disclosure resides in methods of selecting, designing or modifying oligonucleotides such that they exhibit reduced cGAS inhibitory activity.



WO 2022/213153 A1